U.S. Markets closed

IntelliPharmaCeutics International Inc. (IPCI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.94-0.01 (-0.51%)
At close: 4:00PM EDT
People also watch
  • The most POS stock
  • FDA Approval wow!! This is a Buyout Candidate!! Time to stay long on this one. GL
  • What's the breakdown of contribution from generics SEROQUEL and ZETIA for the quarter?


    Paul V. Campanelli, Endo International plc - CEO, President and Director [21]


    Are we getting that?


    Blaise Coleman, Endo International plc - CFO and EVP [22]


    Yes, so for first quarter, we had about $200 million in revenue for quetiapine and ezetimibe combined.

    From Endo conference call
  • NPR reported Trump is moving the opioid epidemic. Good news for IPCI>
  • With Trump talking about the opioid epidemic, I wouldnt be surprised to see BP take shot at these guys.
  • Anything is possible with Trump and again today he mentioned the opioid epidemic. Should help us.
  • who pays Analysts for the hyped up $6.00 target?
  • More ANDA approvals in the near term highly likely:

    Partnered with Mallinkrodt:

    Pristiq, ANDA filed Sep 2012, market volume (US) $889 million
    Lamictal XR, ANDA filed Sep 2011, market volume (US) $519 million

    ANDAs even older:

    Effexor XR, ANDA filed Jan 2010 (!), market volume (US) 648 million
    Protonix, ANDA filed Jan 2010 (!), market volume (US) 336 million

    And we might here about the Seroquel XR ANDS in Canada soon too.
  • Oddis free bank account all risk to investers. is there a connection withvthe Obamas?
  • The CEO said a while back in CC, a PSs for REX would come very soon... anyone know what happened there?
  • I want to see $5 by noon today or oddidi giving meifud an atomic wedgie
  • Does anyone have any idea about Gluc? When will they PS?
  • Revenue Estimate Current Qtr. (May 2017) Next Qtr. (Aug 2017) Current Year Next Year
    No. of Analysts 2 2 2 2
    Avg. Estimate 1.84M 8.91M 26.32M 57.33M
    Low Estimate 1.81M 8.25M 20.44M 33.07M
    High Estimate 1.88M 9.56M 32.19M 81.6M
    Year Ago Sales 556k 555k 2.25M 26.32M
    Sales Growth (year/est) 230.90% 1,505.40% 1,071.30% 117.80%
  • SER approved... I hope PRISTIQ is next.. should see a run up to REX the end of Sept
  • oddidi still has no plan to bring their recently approved generic to market. he has no partner because there is very little profit to be made after factoring in oddidi's royalties. it is just a low margin, generic drug with plenty of competition. he can spend all sorts of money getting these kind of drugs approved but it isn't going to result in partners or revenues.
  • I will remember all the bears here in a year about their postings. ICPI is on track and in a better position than ever before. The Seroquel launch will bring in relevant money and further positive developments are just ahead. Even Purdue will not be able to stop IPCI.
  • which clown gave this stock a 6-8 price target???
  • Rexista will be tied up in court for the next couple years costing the company bundles to litigate~
    ....and they are about out of cash now.

    More dilution is coming much sooner than expected.

    Pretty grim folks.

    This could be a good short candidate near term even though the share price has
    already tumbled -38% for the year. New 52 week low probably in near future......
  • The patent protection on Pristiq expired so we should see some action there... 2 other ANDAs are 7 years old!
  • I wrote 3 weeks ago I got out of this stock when I realized they have no lab or sales force and bigger companies already have most of the same drugs on the market. Pfizfer announced they are coming out with a slow release opioid next year. If rxi's drugs were so great Pfizer would just buy rxi for 60 million instead of going thru the development costs of developing their own. I wish it was a good investment but I just can't see this company ever making any money.